Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ADA | P00813 | 1/20 | 0.30 |
| ▸ | CDA | P32320 | 5/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3995295 | 1.00 | ADORA2A (0.38) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL6040254 | 1.00 | ADORA2A (0.38) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL170812 | 1.00 | ADORA2A (0.38) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL18241620 | 1.00 | ADORA2A (0.38) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL7640916 | 1.00 | ADORA2A (0.38) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL338344 | 0.80 | ADORA2A (0.38) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL1826901 | 0.80 | ADORA2A (0.38) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL338345 | 0.80 | ADORA2A (0.38) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL14293911 | 0.80 | ADORA2A (0.38) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL8722910 | 0.79 | ADORA2A (0.36) | ADORA2AADORA3ADORA1ADORA2BALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584769-B2 | Diterpene glycosides, compositions and purification methods | THE COCA-COLA COMPANY (US) | 2023-02-21 | — | — | US | disclosed |
| US-20170275325-A1 | Novel Diterpene Glycosides, Compositions and Purification Methods | THE COCA-COLA COMPANY | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584769-B2 | Diterpene glycosides, compositions and purification methods | DDOST, GYPA, DAD1 | ADORA2A 4553/4885ADORA3 4291/4885ADORA1 4507/4885 |
| US-20170275325-A1 | Novel Diterpene Glycosides, Compositions and Purification Methods | DDOST, GYPA, DAD1 | ADORA2A 4468/4885ADORA3 4121/4885ADORA1 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.